Application Nr Approved Date Route Status External Links
ANDA207486 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Everolimus Is A Kinase Inhibitor Indicated For The Treatment Of: • Adults With Advanced Renal Cell Carcinoma (Rcc) After Failure Of Treatment With Sunitinib Or Sorafenib. ( 1.3 ) • Adults With Renal Angiomyolipoma And Tuberous Sclerosis Complex (Tsc), Not Requiring Immediate Surgery. ( 1.4 ) 1.3 Renal Cell Carcinoma (Rcc) Everolimus Is Indicated For The Treatment Of Adult Patients With Advanced Rcc After Failure Of Treatment With Sunitinib Or Sorafenib. 1.4 Tuberous Sclerosis Complex (Tsc)-Associated Renal Angiomyolipoma Everolimus Is Indicated For The Treatment Of Adult Patients With Renal Angiomyolipoma And Tsc, Not Requiring Immediate Surgery.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Everolimus

Comments